{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:30:19Z","timestamp":1780396219478,"version":"3.54.1"},"reference-count":185,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,1]]},"DOI":"10.1093\/femspd\/ftx033","type":"journal-article","created":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T12:12:19Z","timestamp":1490011939000},"source":"Crossref","is-referenced-by-count":34,"title":["Novel approaches to Neisseria meningitidis vaccine design"],"prefix":"10.1093","volume":"75","author":[{"given":"Myron","family":"Christodoulides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Heckels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"key\n\t\t\t\t20170419231224_bib1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1365-2958.2000.02061.x","article-title":"Auto-transporter A protein of Neisseria meningitidis: a potent CD4+ T-cell and B-cell stimulating antigen detected by expression cloning","volume":"37","year":"2000","journal-title":"Mol Microbiol"},{"key":"key\n\t\t\t\t20170419231224_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0264-410X(94)90314-X","article-title":"Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes","volume":"12","year":"1994","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1099\/00222615-45-6-419","article-title":"Cloning, sequencing, characterisation and implications for vaccine design of the novel dihydrolipoyl acetyltransferase of Neisseria meningitidis","volume":"45","year":"1996","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20170419231224_bib4","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0264-410X(02)00546-7","article-title":"Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes","volume":"21","year":"2003","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib5","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.vaccine.2005.06.001","article-title":"Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives","volume":"23","year":"2005","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejps.2003.09.006","article-title":"Immunogenicity of meningococcal PorA formulations encapsulated in biodegradable microspheres","volume":"21","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"key\n\t\t\t\t20170419231224_bib7","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine","volume":"282","year":"1970","journal-title":"New Engl J Med"},{"key":"key\n\t\t\t\t20170419231224_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0882-4010(89)90087-9","article-title":"Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide","volume":"6","year":"1989","journal-title":"Microb Pathog"},{"key":"key\n\t\t\t\t20170419231224_bib10","first-page":"533","article-title":"Chemo-immunological studies on conjugate carbohydtae proteins. II. Immunological specificity of synthetic sugar protein antigen","volume":"50","year":"1929"},{"key":"key\n\t\t\t\t20170419231224_bib11","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jadohealth.2016.03.040","article-title":"Prevention of meningococcal infection in the United States: current recommendations and future considerations","volume":"59","year":"2016","journal-title":"J Adolescent Health"},{"key":"key\n\t\t\t\t20170419231224_bib12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1099\/0022-1317-51-9-717","article-title":"Impact of meningococcal C conjugate vaccine in the UK","volume":"51","year":"2002","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20170419231224_bib13","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1128\/IAI.58.9.2875-2881.1990","article-title":"Expression of Neisseria meningitidis iron-regulated outer membrane proteins, including a 70-kilodalton transferrin receptor, and their potential for use as vaccines","volume":"58","year":"1990","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib14","article-title":"Identification of a novel vaccine candidate for group B Neisseria meningitidis","year":"2002","journal-title":"13th International Pathogenic Neisseria Conference"},{"key":"key\n\t\t\t\t20170419231224_bib15","first-page":"E140","article-title":"Meningococcal B vaccine and the vision of a meningitis free world","volume":"56","year":"2015","journal-title":"J Prev Med Hyg"},{"key":"key\n\t\t\t\t20170419231224_bib16","doi-asserted-by":"crossref","first-page":"e0133855","DOI":"10.1371\/journal.pone.0133855","article-title":"Investigation into the antigenic properties and contributions to growth in blood of the meningococcal haemoglobin receptors, HpuAB and HmbR","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170419231224_bib17","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/IAI.01815-14","article-title":"Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins","volume":"83","year":"2015","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib18","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","year":"1991","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170419231224_bib19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20170419231224_bib20","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1128\/IAI.73.4.2222-2231.2005","article-title":"Function of neisserial outer membrane phospholipase A in autolysis and assessment of its vaccine potential","volume":"73","year":"2005","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease","volume":"13","year":"1995","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib22","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","article-title":"Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers","volume":"22","year":"2004","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib23","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1128\/IAI.01338-10","article-title":"Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci","volume":"79","year":"2011","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib24","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","article-title":"Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins","volume":"17","year":"1999","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1586\/14789450.2014.938640","article-title":"Neisseria proteomics for antigen discovery and vaccine development","volume":"11","year":"2014","journal-title":"Expert Rev Proteomics"},{"key":"key\n\t\t\t\t20170419231224_bib26","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1099\/00221287-144-11-3027","article-title":"Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci","volume":"144","year":"1998","journal-title":"Microbiology"},{"key":"key\n\t\t\t\t20170419231224_bib27","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1016\/j.vaccine.2008.05.049","article-title":"Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA","volume":"26","year":"2008","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","article-title":"Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine","volume":"14","year":"1996","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib29","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","year":"2002","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170419231224_bib30","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1016\/j.vaccine.2004.03.047","article-title":"Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins","volume":"22","year":"2004","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib31","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1128\/IAI.71.5.2331-2340.2003","article-title":"Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis","volume":"71","year":"2003","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib32","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0264-410X(99)00423-5","article-title":"Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age","volume":"18","year":"2000","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib33","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","year":"1992","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170419231224_bib34","doi-asserted-by":"crossref","first-page":"8420","DOI":"10.1016\/j.vaccine.2007.09.053","article-title":"Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate","volume":"25","year":"2007","journal-title":"Vaccine"},{"issue":"Suppl 5","key":"key\n\t\t\t\t20170419231224_bib35","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1093\/cid\/civ551","article-title":"Introduction and rollout of a new group A meningococcal conjugate vaccine (PsA-TT) in African Meningitis Belt countries, 2010-2014","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0264-410X(99)00216-9","article-title":"Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers","volume":"18","year":"1999","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170419231224_bib37","first-page":"B18","article-title":"Meningococcal vaccine development\u2014from glycoconjugates against MenACWY to proteins against MenB\u2014potential for broad protection against meningococcal disease","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib38","doi-asserted-by":"crossref","first-page":"e1002027","DOI":"10.1371\/journal.ppat.1002027","article-title":"Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival","volume":"7","year":"2011","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20170419231224_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/cid\/ciq065","article-title":"Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis","volume":"52","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170419231224_bib40","first-page":"B42","article-title":"Meningococcal protein antigens and vaccines","volume":"27","year":"2009","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib41","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/pmic.200500164","article-title":"Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles","volume":"6","year":"2006","journal-title":"Proteomics"},{"key":"key\n\t\t\t\t20170419231224_bib42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/glycob\/cwt102","article-title":"Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: a new perspective for vaccine development","volume":"24","year":"2014","journal-title":"Glycobiology"},{"key":"key\n\t\t\t\t20170419231224_bib43","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","year":"2004","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1084\/jem.144.2.319","article-title":"Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model","volume":"144","year":"1976","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170419231224_bib45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4161\/hv.19619","article-title":"Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM)","volume":"8","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20170419231224_bib46","first-page":"81","article-title":"Outer membrane protein vesicle vaccines for meningococcal disease","volume":"66","year":"2001","journal-title":"Methods Mol Med"},{"key":"key\n\t\t\t\t20170419231224_bib47","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/infdis\/175.2.364","article-title":"Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates","volume":"175","year":"1997","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib49","first-page":"429","article-title":"Exploring the secretomes of microbes and microbial communities using filamentous phage display","volume":"7","year":"2016","journal-title":"Front Microbiol"},{"key":"key\n\t\t\t\t20170419231224_bib50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","year":"2009","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20170419231224_bib51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba\u00ae)","volume":"128","year":"2016","journal-title":"Postgrad Med"},{"key":"key\n\t\t\t\t20170419231224_bib52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/hv.7.2.13717","article-title":"Meningococcal glycoconjugate vaccines","volume":"7","year":"2011","journal-title":"Hum Vaccin"},{"key":"key\n\t\t\t\t20170419231224_bib53","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1084\/jem.28.4.449","article-title":"A report on anti-meningitis vaccination and observations on agglutinins in the blood of chronic meningococcus carriers","volume":"28","year":"1918","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170419231224_bib54","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4161\/hv.5.5.7367","article-title":"Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: a road map for discovering new antigens","volume":"5","year":"2009","journal-title":"Hum Vaccin"},{"key":"key\n\t\t\t\t20170419231224_bib55","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","year":"2006","journal-title":"P Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170419231224_bib56","first-page":"279","article-title":"Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70","volume":"45","year":"1971","journal-title":"Bull World Health Organ"},{"key":"key\n\t\t\t\t20170419231224_bib57","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","year":"1969","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170419231224_bib58","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","year":"1969","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170419231224_bib59","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1128\/CVI.00118-09","article-title":"Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles","volume":"16","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"key\n\t\t\t\t20170419231224_bib60","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1084\/jem.129.6.1385","article-title":"Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state","volume":"129","year":"1969","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170419231224_bib61","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.129.6.1367","article-title":"Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers","volume":"129","year":"1969","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170419231224_bib62","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.129.6.1349","article-title":"Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides","volume":"129","year":"1969","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170419231224_bib63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/003591571701001403","article-title":"The outbreak of cerbrospinal fever at Salisbury in 1914-1915","volume":"10","year":"1917","journal-title":"P Roy Soc Med"},{"key":"key\n\t\t\t\t20170419231224_bib64","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1365-2958.2001.02516.x","article-title":"Identification and characterization of App: an immunogenic autotransporter protein of Neisseria meningitidis","volume":"41","year":"2001","journal-title":"Mol Microbiol"},{"key":"key\n\t\t\t\t20170419231224_bib65","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.vaccine.2011.12.076","article-title":"Recombinant outer membrane secretin PilQ(406-770) as a vaccine candidate for serogroup B Neisseria meningitidis","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib66","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.vaccine.2006.08.001","article-title":"Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib67","doi-asserted-by":"crossref","first-page":"e39718","DOI":"10.1371\/journal.pone.0039718","article-title":"Transcriptional profiling of serogroup B Neisseria meningitidis growing in human blood: an approach to vaccine antigen discovery","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170419231224_bib68","doi-asserted-by":"crossref","first-page":"e0124133","DOI":"10.1371\/journal.pone.0124133","article-title":"Identification and therapeutic potential of a vitronectin binding region of meningococcal Msf","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170419231224_bib69","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.","volume":"21","year":"2003","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170419231224_bib70","first-page":"B3","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","year":"2009","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib71","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future","volume":"9","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20170419231224_bib72","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib73","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/pmic.200700574","article-title":"Immunoproteomic identification of the hypothetical protein NMB1468 as a novel lipoprotein ubiquitous in Neisseria meningitidis with vaccine potential","volume":"8","year":"2008","journal-title":"Proteomics"},{"key":"key\n\t\t\t\t20170419231224_bib74","doi-asserted-by":"crossref","first-page":"e0160403","DOI":"10.1371\/journal.pone.0160403","article-title":"Vaccine potential and diversity of the putative Cell Binding Factor (CBF, NMB0345\/NEIS1825) protein of Neisseria meningitidis","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170419231224_bib75","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vaccine.2005.07.056","article-title":"Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis","volume":"24","year":"2006","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib76","first-page":"pii: e00041\u201300013","article-title":"The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential","volume":"4","year":"2013","journal-title":"MBio"},{"key":"key\n\t\t\t\t20170419231224_bib77","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1016\/j.vaccine.2015.07.032","article-title":"A putative amino acid ABC transporter substrate-binding protein, NMB1612, from Neisseria meningitidis, induces murine bactericidal antibodies against meningococci expressing heterologous NMB1612 proteins","volume":"33","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib78","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1128\/IAI.05019-11","article-title":"The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate","volume":"79","year":"2011","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib79","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/0264-410X(95)00101-6","article-title":"The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis","volume":"13","year":"1995","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib80","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1084\/jem.165.4.1207","article-title":"N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis","volume":"165","year":"1987","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170419231224_bib81","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.4049\/jimmunol.142.10.3585","article-title":"Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1","volume":"142","year":"1989","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170419231224_bib82","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4049\/jimmunol.137.5.1708","article-title":"Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine","volume":"137","year":"1986","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170419231224_bib83","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1128\/IAI.69.6.3809-3816.2001","article-title":"Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci","volume":"69","year":"2001","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib84","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nchem.2396","article-title":"Recent advances in the molecular design of synthetic vaccines","volume":"7","year":"2015","journal-title":"Nat Chem"},{"key":"key\n\t\t\t\t20170419231224_bib85","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.vaccine.2012.12.031","article-title":"Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib86","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","year":"2007","journal-title":"Am J Epidemiol"},{"key":"key\n\t\t\t\t20170419231224_bib87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2567.2004.01971.x","article-title":"Haemophilus influenzae type b conjugate vaccines","volume":"113","year":"2004","journal-title":"Immunology"},{"key":"key\n\t\t\t\t20170419231224_bib88","doi-asserted-by":"crossref","first-page":"26","DOI":"10.11599\/germs.2013.1034","article-title":"DNA vaccines: roles against diseases","volume":"3","year":"2013","journal-title":"Germs"},{"key":"key\n\t\t\t\t20170419231224_bib89","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1128\/IAI.67.7.3533-3541.1999","article-title":"Identification and characterization of TspA, a major CD4(+) T-cell- and B-cell-stimulating Neisseria-specific antigen","volume":"67","year":"1999","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib90","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/j.vaccine.2014.03.068","article-title":"A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA)","volume":"32","year":"2014","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib91","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin","volume":"198","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib92","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.micinf.2006.04.011","article-title":"Immunogenicity and structural characterisation of an in vitro folded meningococcal siderophore receptor (FrpB, FetA)","volume":"8","year":"2006","journal-title":"Microbes Infect"},{"key":"key\n\t\t\t\t20170419231224_bib93","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10517-016-3422-2","article-title":"Serological analysis of immunogenic properties of recombinant meningococcus IgA1 protease-based proteins","volume":"161","year":"2016","journal-title":"Bull Exp Biol Med"},{"key":"key\n\t\t\t\t20170419231224_bib94","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib95","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0264-410X(02)00596-0","article-title":"Transcriptome-based antigen identification for Neisseria meningitidis","volume":"21","year":"2003","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib96","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clinthera.2011.11.027","article-title":"Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom","volume":"34","year":"2012","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20170419231224_bib97","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jinf.2015.09.035","article-title":"The introduction of the meningococcal B (MenB) vaccine (Bexsero\u00ae) into the national infant immunisation programme-new challenges for public health","volume":"71","year":"2015","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20170419231224_bib98","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/archdischild-2015-308928","article-title":"Enter B and W: two new meningococcal vaccine programmes launched","volume":"101","year":"2016","journal-title":"Arch Dis Child"},{"key":"key\n\t\t\t\t20170419231224_bib99","article-title":"Invasive meningococcal disease in infants following the introduction of Bexsero into the national immunization programme in England","year":"2016","journal-title":"20th International Pathogenic Neisseria Conference"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170419231224_bib100","first-page":"B61","article-title":"The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib101","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1128\/IAI.72.1.345-351.2004","article-title":"Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live meningococci","volume":"72","year":"2004","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib102","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1128\/IAI.01062-06","article-title":"Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies","volume":"74","year":"2006","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib103","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0264-410X(91)90318-Z","article-title":"Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins","volume":"9","year":"1991","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib104","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10719-013-9490-x","article-title":"Chemoenzymatic synthesis of immunogenic meningococcal group C polysialic acid-tetanus Hc fragment glycoconjugates","volume":"30","year":"2013","journal-title":"Glycoconjugate J"},{"key":"key\n\t\t\t\t20170419231224_bib105","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2015.07.019","article-title":"Serum bactericidal antibody assays - The role of complement in infection and immunity","volume":"33","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib106","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","year":"2006","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170419231224_bib107","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1084\/jem.168.1.107","article-title":"Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes","volume":"168","year":"1988","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170419231224_bib109","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/infdis\/jit502","article-title":"Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein","volume":"209","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib110","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jinf.2015.05.006","article-title":"A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial","volume":"71","year":"2015","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20170419231224_bib111","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"key\n\t\t\t\t20170419231224_bib112","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","article-title":"New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4","volume":"177","year":"1998","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib113","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib114","doi-asserted-by":"crossref","first-page":"e5940","DOI":"10.1371\/journal.pone.0005940","article-title":"Towards the immunoproteome of Neisseria meningitidis","volume":"4","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170419231224_bib115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jama.1963.63710020008016","article-title":"In vivo and in vitro resistance to sulfadiazine in strains of Neisseria meningitidis","volume":"186","year":"1963","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170419231224_bib116","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1128\/CVI.05683-11","article-title":"Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development","volume":"19","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"key\n\t\t\t\t20170419231224_bib117","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0264-410X(96)00198-3","article-title":"Recombinant Opc meningococcal protein, folded in vitro, elicits bactericidal antibodies after immunization","volume":"15","year":"1997","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib118","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1128\/IAI.72.1.338-344.2004","article-title":"Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity","volume":"72","year":"2004","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib119","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1016\/S0264-410X(01)00008-1","article-title":"Immunogenicity of recombinant class 1 protein from Neisseria meningitidis refolded into phospholipid vesicles and detergent","volume":"19","year":"2001","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib120","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1128\/IAI.72.11.6511-6518.2004","article-title":"Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential","volume":"72","year":"2004","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib121","first-page":"48","article-title":"Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease","volume":"122","year":"2009","journal-title":"N Z Med J"},{"key":"key\n\t\t\t\t20170419231224_bib122","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","year":"2005","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib123","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1016\/j.vaccine.2015.06.046","article-title":"Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines","volume":"33","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib124","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.vaccine.2009.09.128","article-title":"Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes","volume":"28","year":"2009","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib125","first-page":"361","article-title":"Antigen identification starting from the genome: a \"Reverse Vaccinology\" approach applied to MenB","year":"2012"},{"key":"key\n\t\t\t\t20170419231224_bib126","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0264-410X(96)00001-1","article-title":"Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine","volume":"14","year":"1996","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib127","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1042\/BA20010029","article-title":"Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers","volume":"34","year":"2001","journal-title":"Biotechnol Appl Bioc"},{"key":"key\n\t\t\t\t20170419231224_bib128","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1016\/j.vaccine.2006.02.003","article-title":"Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB","volume":"24","year":"2006","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib129","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.vaccine.2013.03.033","article-title":"Immunization with recombinant Chaperonin60 (Chp60) outer membrane protein induces a bactericidal antibody response against Neisseria meningitidis","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib130","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","year":"2000","journal-title":"Science"},{"key":"key\n\t\t\t\t20170419231224_bib131","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(00)03594-7","article-title":"Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170419231224_bib132","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/S0264-410X(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","year":"2001","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib133","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170419231224_bib134","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1017\/S0022172400017976","article-title":"Prophylactic vaccination in epidemic meningococcal meningitis","volume":"32","year":"1932","journal-title":"J Hyg (Lon)"},{"key":"key\n\t\t\t\t20170419231224_bib135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/psc.2482","article-title":"Max Bergmann lecture: protein epitope mimetics in the age of structural vaccinology","volume":"19","year":"2013","journal-title":"J Pept Sci"},{"key":"key\n\t\t\t\t20170419231224_bib136","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/IAI.65.1.55-63.1997","article-title":"Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains","volume":"65","year":"1997","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib137","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/14712598.2015.983897","article-title":"The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy","volume":"15","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"key\n\t\t\t\t20170419231224_bib138","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/infdis\/167.5.1065","article-title":"The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies","volume":"167","year":"1993","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib139","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/IAI.63.12.4642-4652.1995","article-title":"Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine","volume":"63","year":"1995","journal-title":"Infect Immun"},{"issue":"Suppl 5","key":"key\n\t\t\t\t20170419231224_bib140","first-page":"S103","article-title":"Can we control all-cause meningococcal disease in Europe?","volume":"22","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20170419231224_bib141","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1099\/jmm.0.004820-0","article-title":"Neisseria meningitidis antigen NMB0088: sequence variability, protein topology and vaccine potential","volume":"58","year":"2009","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20170419231224_bib142","first-page":"91ra62","article-title":"Rational design of a meningococcal antigen inducing broad protective immunity","volume":"3","year":"2011","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t20170419231224_bib143","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.0800151105","article-title":"Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis","volume":"105","year":"2008","journal-title":"P Natl Acad Sci USA"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170419231224_bib144","first-page":"B87","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib145","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","year":"2010","journal-title":"P Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170419231224_bib146","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba\u00ae): a review in active immunization against invasive meningococcal group B disease in individuals aged 10-25 years","volume":"29","year":"2015","journal-title":"BioDrugs"},{"key":"key\n\t\t\t\t20170419231224_bib147","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","year":"1991","journal-title":"NIPH Ann"},{"key":"key\n\t\t\t\t20170419231224_bib148","first-page":"527","article-title":"Prophylactic vaccination against epidemic meningitis","volume":"59","year":"1912","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170419231224_bib149","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/33046","article-title":"Meningitis bacterium is viable without endotoxin","volume":"392","year":"1998","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170419231224_bib150","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1093\/emboj\/20.24.6937","article-title":"Outer membrane composition of a lipopolysaccharide-deficient Neisseria meningitidis mutant","volume":"20","year":"2001","journal-title":"EMBO J"},{"key":"key\n\t\t\t\t20170419231224_bib151","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.vaccine.2005.07.084","article-title":"Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?","volume":"24","year":"2006","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib152","doi-asserted-by":"crossref","first-page":"e1000969","DOI":"10.1371\/journal.ppat.1000969","article-title":"An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential","volume":"6","year":"2010","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20170419231224_bib153","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1016\/j.vaccine.2005.03.015","article-title":"Identification of novel antigens that protect against systemic meningococcal infection","volume":"23","year":"2005","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib154","first-page":"1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","year":"1999","journal-title":"Jama"},{"key":"key\n\t\t\t\t20170419231224_bib155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0882-4010(89)90074-0","article-title":"Antibody production to a meningococcal outer membrane protein cloned into live Salmonella typhimurium aroA vaccine strain","volume":"6","year":"1989","journal-title":"Microb Pathog"},{"key":"key\n\t\t\t\t20170419231224_bib156","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1126\/science.287.5459.1809","article-title":"Complete genome sequence of Neisseria meningitidis serogroup B strain MC58","volume":"287","year":"2000","journal-title":"Science"},{"issue":"Suppl 5","key":"key\n\t\t\t\t20170419231224_bib157","doi-asserted-by":"crossref","first-page":"S396","DOI":"10.1093\/cid\/civ594","article-title":"The evolution of the meningitis vaccine project","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib158","doi-asserted-by":"crossref","first-page":"28557","DOI":"10.1074\/jbc.273.44.28557","article-title":"The polysialic acid units of the neural cell adhesion molecule N-CAM form filament bundle networks","volume":"273","year":"1998","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20170419231224_bib159","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1128\/JB.146.1.69-78.1981","article-title":"Five structural classes of major outer membrane proteins in Neisseria meningitidis","volume":"146","year":"1981","journal-title":"J Bacteriol"},{"key":"key\n\t\t\t\t20170419231224_bib160","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jprot.2014.02.013","article-title":"Identification of vaccine antigens using integrated proteomic analyses of surface immunogens from serogroup B Neisseria meningitidis","volume":"101","year":"2014","journal-title":"J Proteomics"},{"key":"key\n\t\t\t\t20170419231224_bib161","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1128\/IAI.72.10.5955-5962.2004","article-title":"Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design","volume":"72","year":"2004","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib162","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1021\/pr301208g","article-title":"Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines","volume":"12","year":"2013","journal-title":"J Proteome Res"},{"key":"key\n\t\t\t\t20170419231224_bib163","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1016\/j.vaccine.2010.04.082","article-title":"Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process","volume":"28","year":"2010","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib164","doi-asserted-by":"crossref","first-page":"886","DOI":"10.4161\/hv.7.8.16086","article-title":"Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants","volume":"7","year":"2011","journal-title":"Hum Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib165","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14712598.2015.993375","article-title":"Glycoconjugate vaccines: an update","volume":"15","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"key\n\t\t\t\t20170419231224_bib166","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1179\/2047773214Y.0000000162","article-title":"Bexsero(\u00ae) chronicle","volume":"108","year":"2014","journal-title":"Pathog Glob Health"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170419231224_bib167","first-page":"B10","article-title":"History of meningococcal vaccines and their serological correlates of protection","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib168","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib169","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1006\/mpat.1996.0079","article-title":"Expression of Neisseria meningitidis class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and adjuvants on the production of a bactericidal immune response","volume":"21","year":"1996","journal-title":"Microb Pathog"},{"key":"key\n\t\t\t\t20170419231224_bib170","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.vaccine.2015.11.057","article-title":"Clinical experience with the meningococcal B vaccine, Bexsero(\u00ae): prospects for reducing the burden of meningococcal serogroup B disease","volume":"34","year":"2016","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib171","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1086\/379375","article-title":"Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity","volume":"188","year":"2003","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib172","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1128\/IAI.69.3.1561-1567.2001","article-title":"Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection","volume":"69","year":"2001","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib173","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1128\/IAI.00411-07","article-title":"Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis","volume":"75","year":"2007","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib174","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1128\/IAI.00701-09","article-title":"Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates","volume":"77","year":"2009","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib175","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.vaccine.2013.12.070","article-title":"Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens","volume":"32","year":"2014","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib176","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1128\/IAI.70.8.4028-4034.2002","article-title":"Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis","volume":"70","year":"2002","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib177","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","year":"1972","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170419231224_bib178","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1016\/j.vaccine.2007.04.084","article-title":"Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib179","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/jac\/dkl066","article-title":"Immunogenicity of meningococcal PBP2 during natural infection and protective activity of anti-PBP2 antibodies against meningococcal bacteraemia in mice","volume":"57","year":"2006","journal-title":"J Antimicrob Chemoth"},{"key":"key\n\t\t\t\t20170419231224_bib180","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1128\/IAI.00635-16","article-title":"Meningococcal outer membrane vesicle composition-dependent activation of the innate immune response","volume":"84","year":"2016","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170419231224_bib181","doi-asserted-by":"crossref","first-page":"36575","DOI":"10.1038\/srep36575","article-title":"Modulating endotoxin activity by combinatorial bioengineering of meningococcal lipopolysaccharide","volume":"6","year":"2016","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t20170419231224_bib182","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1586\/14760584.2015.1026808","article-title":"Biosynthetically engineered lipopolysaccharide as vaccine adjuvant","volume":"14","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20170419231224_bib183","first-page":"166","article-title":"Safety of vaccines containing meningococcal group B polysaccharide","volume":"2","year":"1984","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170419231224_bib184","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1016\/j.vaccine.2010.05.006","article-title":"Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine","volume":"28","year":"2010","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170419231224_bib185","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1172\/JCI109383","article-title":"Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man","volume":"63","year":"1979","journal-title":"J Clin Invest"}],"container-title":["Pathogens and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/femspd\/article-pdf\/75\/3\/ftx033\/13686207\/ftx033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T03:57:57Z","timestamp":1719115077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/femspd\/article-lookup\/doi\/10.1093\/femspd\/ftx033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":185,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,22]]},"published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/femspd\/ftx033","relation":{},"ISSN":["2049-632X"],"issn-type":[{"value":"2049-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,22]]}}}